KRAS and familial pancreatic carcinoma: In a genetically engineered pancreatic cancer mouse model (Kras-p53-Cre), immunization with a vector encoding KrasG12D mutation in combination with cyclophosphamide Treg depletion significantly slowed the progression of early PanINs compared to control mice [36].